Casual observers of the beauty industry were undoubtedly astounded when L’Oréal announced in June it was buyingMedik8, a 16-year-old British skincare brand with a great reputation, but hardly Rhode-level frenzy. But those not stuck in social media feeds noticed it had attractive qualities for an acquisition that aren’t always ... The post How Inflexion Helped Engineer Medik8’s Historic $1.1B Exit To L’Oréal appeared first on Beauty Independent.| Beauty Independent
The World Preview webinar will include many data highlights from the report as well as discussion of the big themes in the market.| Evaluate
This international dispute resolution paved the way for progress on more challenging conflicts. How India and Bangladesh came together.| PON - Program on Negotiation at Harvard Law School
Once again, the pharma industry starts a new year with hopes of a recovery. Will 2025 finally see a return of IPOs? Of mega-mergers? Of huge rounds of investment? Perhaps, but more likely this year will simply be a few steps in the right direction. There is still a great deal of uncertainty, particularly around […] The post What Will 2025 Hold for Pharma? appeared first on Evaluate.| Evaluate
One of the great things about working in the pharma industry is the opportunity to listen to very clever people talking about fascinating topics and the latest trends in the market. Events like BIO-Europe are brilliant for this, and there is always plenty to unpack after the panels, keynotes and fireside chats have ended. Our […] The post Three Things we Learned in our “Taking the Pharma Industry Pulse” Webinar appeared first on Evaluate.| Evaluate
Launching a first-in-class drug is high on the wish list of most pharma companies, but achieving that goal is not without its challenges. While patient demand for innovative therapies will always be high, modelling their impact on the treatment landscape is an uncertain business and the stakes are too high to rely on little more […] The post Analogue forecasting: the power of the past to predict the future appeared first on Evaluate.| Evaluate
BIO-Europe took place last week in Stockholm. It’s one of the last big biopharma events of the year and a great time to take stock of where the industry stands as the new year approaches. I was at the convention, taking part in a fireside chat to discuss global innovation trends. Also featuring on the […] The post Join the Discussion: Dealmaking, Innovation and Geopolitics in Pharma appeared first on Evaluate.| Evaluate
Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s Pfizer/Seagen deal, though the Novo/Catalent deal aimed at boosting supplies of the semaglutide products Ozempic and Wegovy is certainly notable. Even so, the 18% increase […] The post 2024 Dealmaking: What’s the Score? appeared first on Evaluate.| Evaluate
2024 has the potential to be a year full of partnering opportunities, driven by the much-discussed patent cliff as some of the biggest-selling drugs in history are set to lose exclusivity by 2028. Perhaps as much as 6% of the nearly $1.6 trillion overall drug market might be at risk and while this isn’t Big […] The post What’s the Deal? Navigating the Complex World of Pharma Business Development appeared first on Evaluate.| Evaluate
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need regular topping up to ensure companies can deliver long-term growth in the face of new competition, and loss of exclusivity. At Evaluate, we work closely […] The post Next Generation Dealmaking with Evaluate and Inpart appeared first on Evaluate.| Evaluate
The first half of the year showed some promise. Did the third quarter continue the trend? Well… If you read our round up of the state of the biopharma market at the halfway point of the year, you may have come away with, if not a spring in your step, then a least a little […] The post Quick View: Biopharma Dealmaking in Q3 appeared first on Evaluate.| Evaluate
You may have read the report, you may have pondered the infographic, but the best way to really get under the skin of the Evaluate World Preview report is to join the webinar. As well as sharing the highlights of the data from the report, the webinar gave our presenters a chance to really discuss […] The post In Case You Missed It: Three Things We Learned In Our World Preview Webinar appeared first on Evaluate.| Evaluate
In December of 2022, Kite and Arcellx entered an agreement to develop and commercialise Arcellx’s multiple myeloma product candidate CART-ddBCMA. The candidate is currently in Phase 2 clinical development and is a cell therapy product comprising of genetically modified autologous T cells. The collaboration brings together Arcellx’s promising CART-ddBCMA therapy with Kite’s expertise and leadership […] The post BioSci Deal of the Month – Kite & Arcellx appeared first on Evaluate.| Evaluate
In September of 2022, GSK and Spero Therapeutics entered into an exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr. Tebipenem HBr is an oral carbapenem antibiotic aimed at treating complicated urinary tract infections including pyelonephritis. GSK will receive an exclusive license to develop and commercialise Tebipenem pivoxil and tebipenem pivoxil HBr in all territories […] The post BioSci Deal of the Month – Spero Therapeutics & GSK appeared first on Evaluate.| Evaluate
In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544). IRAK4 is a serine-threonine protein kinase known to be present and active in the occurrence of certain immunity responses, inflammation disorders, and various cancers. Under the terms of this agreement, Kainos will study […] The post BioSci Deal of the Month – Kainos Medicines & Emmaus Life Sciences appeared first on Evaluate.| Evaluate
Missed our World Preview webinar? Check it out on-demand to get the highlights from our panel as they discuss the latest pharma forecasts.| Evaluate
Over the last 10 years, large pharma companies have spent an average of $120bn across pharma R&D and business development investments.| Evaluate
Our World Preview report features pharma forecasts out to 2030. The theme this year is “Pharma’s Growth Boost”.| Evaluate
Neurology is experiencing a revival with notable clinical advancements and increased deal activity from pharmaceutical giants.| Evaluate